- Cidara Therapeutics (NASDAQ:CDTX) initiated with Buy rating by Cantor Fitzgerald.
- Ohr Pharmaceuticals (NASDAQ:OHRP) initiated with Buy rating and $10 (223% upside) price target by H.C. Wainwright.
- Sarepta Therapeutics (NASDAQ:SRPT) initiated with Equal Weight rating and $53 (28% upside) price target by Morgan Stanley.
- AMAG Pharmaceuticals (NASDAQ:AMAG) initiated with Buy rating and $40 (58% upside) price target by Needham.
- Nabriva Therapeutics (NASDAQ:NBRV) initiated with Outperform rating and $14 (138% upside) price target by Leerink Swann.
- Paratek Pharmaceuticals (NASDAQ:PRTK) initiated with Outperform rating and $23 (107% upside) price target by Leerink Swann.
- Glaukos (NYSE:GKOS) initiated with Outperform rating and $42 (midpoint) (26% upside) price target by Wells Fargo.
- Calithera Biosciences (NASDAQ:CALA) initiated with Sell rating and $1 (62% downside risk) price target by Citigroup.
- Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (173% upside) price target by Aegis Capital.
- Clovis Oncology (NASDAQ:CLVS) initiated with Sell rating and $15 (50% downside risk) price target by Chardan Capital.
- Fulgent Genetics (NASDAQ:FLGT) initiated with Overweight rating and $13 (42% upside) price target by Piper Jaffray. Initiated with Buy rating and $15 (64% upside) price target by BTIG Research.
- Tabula Rosa Healthcare (NASDAQ:TRHC) initiated with Outperform rating and $17 (38% upside) price target by Wells Fargo.
- Xenon Pharmaceuticals (NASDAQ:XENE) initiated with Buy rating and $18 (121% upside) price target by Stifel Nicolaus.
Healthcare ratings roundup - new coverage
Recommended For You
About CDTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CDTX | - | - |
Cidara Therapeutics, Inc. |